Facilely synthesized polydopamine encapsulated surface-enhanced Raman scattering (SERS) probes for multiplex tumor associated cell surface antigen detection using SERS imaging

RSC Advances ◽  
2015 ◽  
Vol 5 (88) ◽  
pp. 72369-72372 ◽  
Author(s):  
Changlong Sun ◽  
Ling Zhang ◽  
Ren Zhang ◽  
Mingxia Gao ◽  
Xiangmin Zhang
Keyword(s):  
Cell Surface ◽  
Raman Scattering ◽  
Surface Antigen ◽  
Surface Antigens ◽  
Cell Surface Antigen ◽  
Cell Surface Antigens ◽  
Surface Enhanced ◽  
Surface Enhanced Raman ◽  
Enhanced Raman Scattering ◽  
Sers Imaging

A novel SERS probes fabrication were studies and used for multiplex tumor associated cell surface antigens detection using SERS imaging.

Surface-enhanced Raman scattering (SERS) imaging of bioactive metabolites in mixed bacterial populations

2019 ◽  
Vol 14 ◽  
pp. 207-215 ◽  
Author(s):  
Sarah De Marchi ◽  
Gustavo Bodelón ◽  
Lorena Vázquez-Iglesias ◽  
Luis M. Liz-Marzán ◽  
Jorge Pérez-Juste ◽  
...  
Keyword(s):  
Raman Scattering ◽  
Surface Enhanced Raman Scattering ◽  
Bioactive Metabolites ◽  
Bacterial Populations ◽  
Surface Enhanced ◽  
Surface Enhanced Raman ◽  
Enhanced Raman Scattering ◽  
Sers Imaging

scholarly journals ALPPL2 is a highly specific and targetable tumor cell surface antigen

2020 ◽  
Author(s):  
Yang Su ◽  
Xin Zhang ◽  
Scott Bidlingmaier ◽  
Christopher R. Behrens ◽  
Nam-Kyung Lee ◽  
...  
Keyword(s):  
Cell Surface ◽  
Tumor Cell ◽  
Surface Antigen ◽  
Tissue Specificity ◽  
Surface Antigens ◽  
Cell Surface Antigen ◽  
Cell Surface Antigens ◽  
Normal Tissues ◽  
Specific Tumor ◽  
Therapy Development

AbstractIt has been challenging to identify tumor-specific cell surface antigens as the vast majority of tumor-associated antigens are also expressed by some normal tissues. In the course of our study on mesothelioma, we identified a highly specific tumor cell surface antigen that can be targeted for therapy development. Mesothelioma is caused by malignant transformation of the mesothelium, incurable and categorized into three histological subtypes, epithelioid, biphasic and sarcomatoid. To identity novel mesothelioma cell surface antigens with broad subtype coverage and high tissue specificity, we have previously selected phage antibody display libraries on live mesothelioma cells and tissues following counter-selection on normal cells, and identified a panel of human antibodies that bind all subtypes of mesothelioma but not normal mesothelium. One of the antibodies, M25, showed high specificity, and we hereby report the identification of the M25 antigen as ALPPL2. We performed immunohistochemistry on normal human tissues and found that ALPPL2 is expressed only on placental trophoblasts but not any other normal tissues. This exquisite tissue specificity and broad tumor type coverage suggests that ALPPL2 could be an excellent cell surface target for therapeutic development against mesothelioma. To evaluate therapeutic potential of ALPPL2 targeting, we developed an ALPPL2-targeted antibody-drug conjugate and demonstrated potent and specific tumor killing in vitro and in vivo against both epithelioid and sarcomatoid mesothelioma. Thus ALPPL2 belongs to a rare class of cell surface antigens that can be said as being truly tumor specific and is well suited for therapy development against ALPPL2 expressing tumors.

Targeting CLL Cells Using Rituximab-Conjugated Surface Enhanced Raman Scattering (SERS) Gold Nanoparticles

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2691-2691
Author(s):  
Edward Parker ◽  
Christina MacLaughlin ◽  
Samantha Wala ◽  
Gilbert Walker ◽  
Chen Wang
Keyword(s):  
Cell Surface ◽  
Raman Scattering ◽  
Lymphoproliferative Disorders ◽  
Surface Marker ◽  
Therapeutic Antibody ◽  
Surface Enhanced ◽  
Surface Enhanced Raman ◽  
Enhanced Raman Scattering ◽  
Marker Detection

Abstract Abstract 2691 Measuring the expression of cell surface markers is crucial to the effective diagnosis of lymphoproliferative disorders such as chronic lymphocytic leukemia (CLL). However, conventional fluorescent probes are constrained by the degradative effect of photobleaching and the broad emission spectra of dyes, which restricts the multiplexing capacity of marker detection. Recent developments in nanoparticle-based technology may confer significant advantages over these traditional tools. In particular, surface enhanced Raman scattering (SERS) nanoparticles (NPs) can now be targeted to cells via conjugation to monoclonal antibodies. These particles are composed of colloidal gold cores surrounded by an organic dye with a distinct Raman-scattering signature. In addition to providing stable long-term signals, Raman probes typically exhibit spectral bands more than 30 times narrower than those of fluorescence techniques, thereby greatly increasing the multiplexing potential of phenotypic analysis. In this study, we developed SERS NPs conjugated to the monoclonal antibody rituximab in order to target the surface marker CD20. Rituximab has been established as an effective therapeutic antibody in the treatment of several B-cell disorders, though its precise mechanism of action is unclear. The preparation of SERS probes was achieved by coating 60 nm gold particles with the Raman-active reporter malachite green isothiocyanate (MGITC) followed by a stabilizing layer of polyethylene glycol (PEG). These particles were then covalently linked to rituximab using ethyl dimethylaminopryl carbiimide (EDC) and sulfo-NHS chemistry. Following the incubation of CLL cells with rituximab conjugates, samples were examined using darkfield microscopy, and Raman scatter analyzed using a Raman spectroscope. The resulting spectra were concordant with the successful retention of SERS probes, as indicated by an increase in the intensity of MGITC Raman peaks as the staining concentration of conjugates increased. However, the significant background signal obtained using unconjugated control NPs highlights the necessity to incorporate more rigorous steps to remove unbound particles in future studies. Darkfield imaging strongly confirmed the successful binding of SERS probes to CLL cells, which notably failed to retain control NPs. Conjugate targeting was also disrupted by blocking CD20 binding sites with unconjugated rituximab prior to SERS probe staining, thereby confirming that NP targeting was not the product of non-specific binding. Together, these results strongly indicate the successful incorporation of a therapeutic antibody into the NP-based targeting of CD20. In conjunction with SERS probes directed at other markers, this novel diagnostic approach could have a profound impact on the multiplexing capacity of cell surface marker detection during the diagnosis of lymphoproliferative disorders. In addition, the long-term stability of these probes might facilitate the use of NP conjugates as tracers to examine the effects of rituximab binding, thereby providing valuable insight into the mechanisms of antibody-based immunotherapy. Disclosures: No relevant conflicts of interest to declare.

scholarly journals A cell surface antigen of the mouse related to xenotropic MuLv defined by naturally occurring antibody and monoclonal antibody. Relation to Gix G(rada1), G(aksl2) systems of MuLV-related antigens.

1981 ◽  
Vol 154 (3) ◽  
pp. 659-675 ◽  
Author(s):  
Y Obata ◽  
E Stockert ◽  
A B DeLeo ◽  
P V O'Donnell ◽  
H W Snyder ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cell Surface ◽  
Surface Antigen ◽  
Biochemical Characterization ◽  
Surface Antigens ◽  
Lymphoid Cells ◽  
Cell Surface Antigen ◽  
Mouse Strains ◽  
Cell Surface Antigens ◽  
Naturally Occurring

A new cell surface antigen of the mouse related to xenotropic murine leukemia virus (MuLV) is described. The antigen, designated G(erld), is defined by cytotoxic tests with the B6-x-ray-induced ERLD and naturally occurring antibody. G(erld) is distinct from all previously defined cell surface antigens. Monoclonal antibody with the same specificity has been developed. Inbred mouse strains are classified as G(erld)+ or G(erld)- according to the presence of absence of the antigen on lymphoid cells. G(erld)+ strains differ with regard to quantitative expression of G(erld) on normal thymocytes. The emergence of G(erld)+ tumors in G(erld)- strains indicates the presence of genes coding for the antigen even in strains not normally expressing the antigen. G(erld) has the characteristic of a differentiation antigen in normal mice. In G(erld)+ strains, high levels of the antigen are found on thymocytes with lower levels being detected on cells of spleen, lymph nodes and bone marrow. No G(erld) was detected in brain or kidney or on erythrocytes. The segregation ratios for G(erld) expression on thymocytes in backcross and F2 mice of crosses between G(erld)+ (B6, 129, and B6-Gix+) and G(erld)- (BALB/c) strains suggest that G(erld) expression is controlled by a single locus in B6, by two unlinked loci in 129, and by three unlinked loci in B6-Gix+ mice. Induction of the antigen by MuLV infection of permissive cells in vitro indicates that G(erld) is closely related to xenotropic and dualtropic MuLV; all xenotropic and dualtropic MuLV tested induced the antigen, whereas the majority of ecotropic and the two amphotropic MuLV failed to do so. As dualtropic MuLV are thought to be recombinants between ecotropic and xenotropic MuLV sequences, G(erld) coding by dualtropic MuLV may signify the contribution of the xenotropic part in the recombinational event. Serological and biochemical characterization indicates that G(erld) is related to the gp 70 component of the MuLV envelope. The relation of G(erld) to the previously defined gp 70-related cell surface antigens (Gix, G(rada), and G(aksl2) is discussed, particularly with regard to their characteristics as differentiation antigens, the genetic origin of dualtropic MuLV, and the leukemogenicity of MuLV.

Sign in / Sign up

Export Citation Format

Share Document